The FLAURA2 trial establishes a new standard of care for EGFR-mutated NSCLC, according to the authors of new research.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/first-line-osimertinib-plus-chemo-extends-survival-nsclc-2025a1000nll?src=rss
Author :
Publish date : 2025-09-08 00:28:00
Copyright for syndicated content belongs to the linked Source.
